Anonymous
Guest
Anonymous
Guest
I hear many have left and many are planning on leaving. Is it really that bad?
So bad once people don't have to pay back their sign on bonus watch out. The division is run by primary care managers in a biotech arena. Gilenya could be a billion dollar drug but Novartis hired the wrong leaders.
So bad once people don't have to pay back their sign on bonus watch out. The division is run by primary care managers in a biotech arena. Gilenya could be a billion dollar drug but Novartis hired the wrong leaders.
Hell if I lived in Mississippi, I would leave too!
???
Novartis is slowly crumbling from within. Pipeline is not performing and branded $billion products are soon to be generic. Management will put the pressure on the reps and goals increased to make it look like it's a problem with the field - including Regionals, managers and the reps.
It's going to be a heck of a ride!
I can't figure out why they insisted on hiring so many reps with MS experience but don't allow us to use that experience. You can't say anything about it or you're a "complainer". Upper management is comprised of people who were next in line for promotions, not people with the experience to sell in this complicated market. They probably took the job just for their resume to move on quickly to the next level = uninvested in the results. Great drug, poorly run division. Just wait until Teva and Biogen show Novartis how a pill should really be marketed right out of the gate... sad.
Rumor yesterday - if you were a new hire and are performing in bottom 1/3 as of 12/11, you will be replaced 1/12.
Rumor yesterday - if you were a new hire and are performing in bottom 1/3 as of 12/11, you will be replaced 1/12.
Hell if I lived in Mississippi, I would leave too!
Novartis upper management has no idea what is to come when Buyogen launches BG12. They will see a company launch an oral with comparative marketing materials right out of the gate and a sales team that will stop at nothing to get business. Novartis MS newbies are about to get a rude awakening to the hostile MS market place. Bet you that Buy O Gen has more marketing info, data, etc. before Gilenya does....and we had a 1 year head start. I was around for Avonex and Tysabri launches and can tell you that the Gilenya launch has no comparisons. Buyogen would have fired the marketing team and upper management.[/
It's the compliance department that is running the company. They should of sold the drug to a biotech company. Upper management has no clue go back to primary care.